Pregnancy among patients with chronic myeloid leukemia treated with imatinib

Patricia Ault, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Miloslav Beran, Mary Beth Rios, Charles Koller, Francis Giles, Michael Keating, Moshe Talpaz, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Purpose: Imatinib has potential teratogenicity in animals, but the effect of exposure to imatinib during conception and pregnancy in humans is not known. Patients and Methods: The records of all patients with chronic myeloid leukemia (CML) treated with imatinib were reviewed. We report the experience on 19 pregnancies involving 18 patients (10 females and eight males) who conceived while receiving imatinib for the treatment of CML. Results: All female patients discontinued therapy immediately on recognition of pregnancy. Three pregnancies (involving two female patients and one male patient) ended in spontaneous abortion, and one patient had an elective abortion. All other pregnancies were uneventful. Two of the 16 babies had minor abnormalities at or shortly after birth (hypospadias in one baby and rotation of small intestine in one baby) that were surgically repaired. All babies have continued normal growth and development. Among female patients who interrupted therapy, five of nine in complete hematologic remission (CHR) at the time of treatment interruption eventually lost CHR, and six experienced an increase in Philadelphia chromosome-positive metaphases. At a median of 18 months after resuming therapy with imatinib, eight patients had a cytogenetic response (complete in three patients). Conclusion: Although there is no evidence that a brief exposure to imatinib during conception and pregnancy adversely affects the developing fetus, most patients lose their response after treatment interruption. Patients receiving imatinib should be advised to practice adequate contraception.

Original languageEnglish (US)
Pages (from-to)1204-1208
Number of pages5
JournalJournal of Clinical Oncology
Volume24
Issue number7
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pregnancy
Imatinib Mesylate
Therapeutics
Philadelphia Chromosome
Hypospadias
Spontaneous Abortion
Metaphase
Contraception
Growth and Development
Cytogenetics
Small Intestine
Fetus
Parturition

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pregnancy among patients with chronic myeloid leukemia treated with imatinib. / Ault, Patricia; Kantarjian, Hagop; O'Brien, Susan; Faderl, Stefan; Beran, Miloslav; Rios, Mary Beth; Koller, Charles; Giles, Francis; Keating, Michael; Talpaz, Moshe; Cortes, Jorge.

In: Journal of Clinical Oncology, Vol. 24, No. 7, 01.03.2006, p. 1204-1208.

Research output: Contribution to journalArticle

Ault, P, Kantarjian, H, O'Brien, S, Faderl, S, Beran, M, Rios, MB, Koller, C, Giles, F, Keating, M, Talpaz, M & Cortes, J 2006, 'Pregnancy among patients with chronic myeloid leukemia treated with imatinib', Journal of Clinical Oncology, vol. 24, no. 7, pp. 1204-1208. https://doi.org/10.1200/JCO.2005.04.6557
Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. Journal of Clinical Oncology. 2006 Mar 1;24(7):1204-1208. https://doi.org/10.1200/JCO.2005.04.6557
Ault, Patricia ; Kantarjian, Hagop ; O'Brien, Susan ; Faderl, Stefan ; Beran, Miloslav ; Rios, Mary Beth ; Koller, Charles ; Giles, Francis ; Keating, Michael ; Talpaz, Moshe ; Cortes, Jorge. / Pregnancy among patients with chronic myeloid leukemia treated with imatinib. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 7. pp. 1204-1208.
@article{bbe1e8c144f94b60bb5c13c267093791,
title = "Pregnancy among patients with chronic myeloid leukemia treated with imatinib",
abstract = "Purpose: Imatinib has potential teratogenicity in animals, but the effect of exposure to imatinib during conception and pregnancy in humans is not known. Patients and Methods: The records of all patients with chronic myeloid leukemia (CML) treated with imatinib were reviewed. We report the experience on 19 pregnancies involving 18 patients (10 females and eight males) who conceived while receiving imatinib for the treatment of CML. Results: All female patients discontinued therapy immediately on recognition of pregnancy. Three pregnancies (involving two female patients and one male patient) ended in spontaneous abortion, and one patient had an elective abortion. All other pregnancies were uneventful. Two of the 16 babies had minor abnormalities at or shortly after birth (hypospadias in one baby and rotation of small intestine in one baby) that were surgically repaired. All babies have continued normal growth and development. Among female patients who interrupted therapy, five of nine in complete hematologic remission (CHR) at the time of treatment interruption eventually lost CHR, and six experienced an increase in Philadelphia chromosome-positive metaphases. At a median of 18 months after resuming therapy with imatinib, eight patients had a cytogenetic response (complete in three patients). Conclusion: Although there is no evidence that a brief exposure to imatinib during conception and pregnancy adversely affects the developing fetus, most patients lose their response after treatment interruption. Patients receiving imatinib should be advised to practice adequate contraception.",
author = "Patricia Ault and Hagop Kantarjian and Susan O'Brien and Stefan Faderl and Miloslav Beran and Rios, {Mary Beth} and Charles Koller and Francis Giles and Michael Keating and Moshe Talpaz and Jorge Cortes",
year = "2006",
month = "3",
day = "1",
doi = "10.1200/JCO.2005.04.6557",
language = "English (US)",
volume = "24",
pages = "1204--1208",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Pregnancy among patients with chronic myeloid leukemia treated with imatinib

AU - Ault, Patricia

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Beran, Miloslav

AU - Rios, Mary Beth

AU - Koller, Charles

AU - Giles, Francis

AU - Keating, Michael

AU - Talpaz, Moshe

AU - Cortes, Jorge

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Purpose: Imatinib has potential teratogenicity in animals, but the effect of exposure to imatinib during conception and pregnancy in humans is not known. Patients and Methods: The records of all patients with chronic myeloid leukemia (CML) treated with imatinib were reviewed. We report the experience on 19 pregnancies involving 18 patients (10 females and eight males) who conceived while receiving imatinib for the treatment of CML. Results: All female patients discontinued therapy immediately on recognition of pregnancy. Three pregnancies (involving two female patients and one male patient) ended in spontaneous abortion, and one patient had an elective abortion. All other pregnancies were uneventful. Two of the 16 babies had minor abnormalities at or shortly after birth (hypospadias in one baby and rotation of small intestine in one baby) that were surgically repaired. All babies have continued normal growth and development. Among female patients who interrupted therapy, five of nine in complete hematologic remission (CHR) at the time of treatment interruption eventually lost CHR, and six experienced an increase in Philadelphia chromosome-positive metaphases. At a median of 18 months after resuming therapy with imatinib, eight patients had a cytogenetic response (complete in three patients). Conclusion: Although there is no evidence that a brief exposure to imatinib during conception and pregnancy adversely affects the developing fetus, most patients lose their response after treatment interruption. Patients receiving imatinib should be advised to practice adequate contraception.

AB - Purpose: Imatinib has potential teratogenicity in animals, but the effect of exposure to imatinib during conception and pregnancy in humans is not known. Patients and Methods: The records of all patients with chronic myeloid leukemia (CML) treated with imatinib were reviewed. We report the experience on 19 pregnancies involving 18 patients (10 females and eight males) who conceived while receiving imatinib for the treatment of CML. Results: All female patients discontinued therapy immediately on recognition of pregnancy. Three pregnancies (involving two female patients and one male patient) ended in spontaneous abortion, and one patient had an elective abortion. All other pregnancies were uneventful. Two of the 16 babies had minor abnormalities at or shortly after birth (hypospadias in one baby and rotation of small intestine in one baby) that were surgically repaired. All babies have continued normal growth and development. Among female patients who interrupted therapy, five of nine in complete hematologic remission (CHR) at the time of treatment interruption eventually lost CHR, and six experienced an increase in Philadelphia chromosome-positive metaphases. At a median of 18 months after resuming therapy with imatinib, eight patients had a cytogenetic response (complete in three patients). Conclusion: Although there is no evidence that a brief exposure to imatinib during conception and pregnancy adversely affects the developing fetus, most patients lose their response after treatment interruption. Patients receiving imatinib should be advised to practice adequate contraception.

UR - http://www.scopus.com/inward/record.url?scp=33644984830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644984830&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.04.6557

DO - 10.1200/JCO.2005.04.6557

M3 - Article

C2 - 16446320

AN - SCOPUS:33644984830

VL - 24

SP - 1204

EP - 1208

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -